What Causes Hidradenitis Suppurativa?—15 Years After

    October 2020 in “ Experimental Dermatology
    Christos C. Zouboulis, Farida Benhadou, Angel As Byrd, Nisha Ns Chandran, Evangelos J. Giamarellos‐Bourboulis, Gabriella Fabbrocini, John W. Frew, Hideki Fujita, Marcos A. González‐López, Philippe Guillem, Wayne Gulliver, Iltefat Hamzavi, Yıldız Hayran, Barbara Hórvath, Sophie Hüe, R. M. Hunger, John R. Ingram, Gregor B. E. Jemec, Jun Qiang, Alexa B. Kimball, Joslyn S. Kirby, Maria Mp Konstantinou, Michelle Ma Lowes, Amanda S. MacLeod, A. Martorell, Angelo Valerio Marzano, Łukasz Matusiak, Aude Nassif, Elena Nikiphorou, Georgios Nikolakis, André Nogueira da Costa, Martin Okun, Lauren A V Orenstein, José C. Pascual, Ralf Paus, B Périn, Errol P. Prens, Till Ta Röhn, Andrea Szegedi, Jacek C. Szepietowski, Thrasyvoulos Tzellos, Baoxi Wang, Hessel H. van der Zee
    Image of study
    TLDR Hidradenitis suppurativa is caused by genetic factors, inflammation, bacteria, hormones, and lifestyle factors like obesity and smoking.
    Over the past 15 years, significant progress was made in understanding the multifactorial causes of hidradenitis suppurativa (HS). Research revealed that HS is a polygenic, autoinflammatory disease involving dysregulated gene pathways, genetic mutations, and microbiome contributions. Pro-inflammatory cytokines like IL-1ß, IL-17, IL-23, and TNF-α played central roles, leading to targeted treatments such as adalimumab. Genetic studies identified a higher risk in individuals with more than six copies of the ß-defensin gene cluster. The role of bacterial infections, autoimmunity, and hormonal influences, particularly androgens, were also explored. HS was associated with cardiovascular risks, obesity, insulin resistance, and smoking, which exacerbated the condition. The involvement of hair follicles and apocrine glands, along with shared inflammatory pathways with alopecia areata, was noted. Despite these advances, the exact mechanisms remained complex, necessitating further research for personalized treatment approaches and improved patient outcomes.
    Discuss this study in the Community →

    Research cited in this study

    9 / 9 results

    Related Community Posts Join

    1 / 1 results

      community Diagnosed with MPB at 16 (Male)

      in Treatment  54 upvotes 6 months ago
      A 16-year-old diagnosed with male pattern baldness (MPB) was prescribed hair vitamins, vitamin D, a non-ketoconazole shampoo, and redenysl + serum, with a suggestion for GFC or IHRF treatments. Some users recommended minoxidil, ketoconazole, and derma stamping, while others advised against certain treatments until the age of 18.

    Similar Research

    5 / 684 results